Andy Pettitte’s complicated Hall of Fame case

60 Comments

Andy Pettitte was never a dominant starter. That’s pretty much indisputable.

In 18 big-league seasons, Pettitte has never won a Cy Young Award, an ERA title or a strikeout crown. The only “black ink” on his Baseball-Reference page comes from the three times he led or shared his league lead in games started. He’s thrown four career shutouts, which is one more than Justin Masterson has this year.

Yet here he is. As he retires for a second time, he leaves MLB as the active leader in wins with 255 and strikeouts with 2,437 and the all-time leader with 19 postseason victories.

So, yeah, Pettitte’s Hall of Fame case is based largely on wins, which should lead to a great deal of skepticism given that he spent most of his career pitching for baseball’s most successful franchise. Among pitchers with at least 300 decisions since 1901, Pettitte ranks 16th with a .627 winning percentage, ahead of obvious Hall of Famers like Tom Seaver, Carl Hubbell, Warren Spahn, Bob Gibson and even Walter Johnson. Make the cutoff 400 decisions instead and Pettitte jumps all of the way to eighth on the list.

One could argue that says as much about the Yankees as it does about Pettitte.

On the other hand, it might surprise people to see Pettitte currently sitting with a 117 ERA+. That’s not Jack Morris territory (he’s at 105). That’s squarely in the Hall of Fame range. Baseball-reference’s Play Index gives us 51 Hall of Fame starting pitchers since 1901. Pettitte’s ERA would sit right along sign Gaylord Perry at No. 30 in that group. It’s better than Steve Carlton and Fergie Jenkins at 115. It’s much better than Don Sutton’s 108. It’s just below Bert Blyleven at 118.

Of course, Pettitte didn’t pitch as much as those guys. Jenkins has the low innings total of that group at 4,500. Pettitte is currently at 3,300. And given that modest innings total, one would certainly like to see more dominance than Pettitte offers.

Going by Baseball-Reference’s WAR, Pettitte’s 60.4 puts him right around Hall of Famers Juan Marichal (61.8), Jim Bunning (60.5) and Hal Newhouser (60.4) and ahead of guys like Whitey Ford (53.9), Early Wynn (51.6) and Catfish Hunter (36.5). But it also ranks behind non-Hall of Famers like Kevin Brown (68.7), Rick Reuschel (68.2), Luis Tiant (65.9) and David Cone (61.8). WAR rates question marks Mike Mussina (82.7) and Curt Schilling (80.7) as much more deserving.

So, Pettitte’s Hall of Fame case largely comes down to two things: the postseason and doping. Some will disqualify him automatically based on his admitted hGH use. I think that’s a discussion for a different time, though. The postseason is of more interest to me here. Pettitte clearly deserves some sort of boost for making 44 postseason starts and going 19-11 with a 3.81 ERA. He has five World Series rings, and he wasn’t a bystander for any of them.

How much credit is the tough part. I’m sympathetic to both sides of the argument. If Pettitte had been drafted by any team other than the Yankees, it’d doubtful he’d have any Hall of Fame case right now. His career is hardly any different than Chuck Finley’s.

On the other hand, Pettitte made the most of the opportunities he was given. And he’s pitched the equivalent of an extra season and a third. Would Pettitte’s regular-season numbers look better if he didn’t so often make an extra five or six starts in October? I think they probably would.

Personally, I think Pettitte still comes up short. I like my Hall of Famers to have higher peaks — to have been among the best players in their leagues, even if only for a couple of years. But it’s unfair to dismiss his case as just being Yankee hype. He has a better argument than Jack Morris, and there are certainly worse pitchers enshrined already. But there are better ones to pick from, too.

Jacob deGrom, oft-injured Rangers ace, to have season-ending right elbow surgery

rangers degrom
Charles LeClaire/USA TODAY Sports
2 Comments

ARLINGTON, Texas — The Texas Rangers signed Jacob deGrom to a $185 million, five-year deal in free agency last winter hoping the two-time NL Cy Young Award winner could help them get back to the playoffs for the first time since 2016 and make a push toward winning a World Series.

They also knew the risks, with the pitcher coming off two injury-plagued seasons with the New York Mets.

Even with deGrom sidelined since late April, the AL West-leading Rangers are off to the best start in franchise history – but now will be without their prized acquisition until at least next year. The team said Tuesday that deGrom will have season-ending surgery next week to repair a torn ulnar collateral ligament in his right elbow.

“We’ve got a special group here and to not be able to be out there and help them win, that stinks,” deGrom said, pausing several times with tears in his eyes. “Wanting to be out there and helping the team, it’s a disappointment.”

General manager Chris Young said Tuesday the decision on surgery came after an MRI on deGrom’s ailing right elbow, but the extent of what is required might not be determined until the operation is performed next week.

Tommy John surgery, in which the damaged ligament is replaced, is often needed to fix a torn UCL, but Young and the Rangers didn’t go as far as saying the pitcher would have that particular procedure. After being drafted by the New York Mets in 2010, deGrom made six starts in the minors that summer before needing Tommy John surgery and missing all of 2011, three years before his big league debut.

DeGrom last pitched April 28 against the New York Yankees, when he exited early because of injury concerns for the second time in a span of three starts. The announcement about surgery came a day after deGrom was transferred to the 60-day injured list.

Young said the latest MRI showed more inflammation and significant structural damage in the ligament that wasn’t there on the scan after deGrom left the game against the Yankees.

“The results of that MRI show that we have not made progress. And in fact, we’ve identified some damage to the ligament,” Young said. “It’s obviously a tough blow for Jacob, for certainly the Rangers. But we do feel this is what is right for Jacob in his career. We’re confident he’ll make a full recovery.”

Young and deGrom, who turns 35 later this month, said the goal is for the pitcher to return near the end of next season. Both said they were glad to have clarity on what was wrong with the elbow.

Texas won all six games started by deGrom (2-0), but the right-hander threw only 30 1/3 innings. He has a 2.67 ERA with 45 strikeouts and four walks. He threw 3 2/3 scoreless innings against the Yankees in his last start before leaving because of discomfort in his arm.

The Rangers went into Tuesday night’s game against St. Louis with a 39-20 record, the first time they were 19 games over .500 since the end of 2016, their last winning season.

Before going home to Florida over the weekend for the birth of his third child, deGrom threw his fifth bullpen last Wednesday in Detroit.

“I’d have days where I’d feel really good, days where I didn’t feel great. So I was kind of riding a roller coaster there for a little bit,” deGrom said. “They said originally there, we just saw some inflammation. … Getting an MRI right after you pitch, I feel like anybody would have inflammation. So, you know, I was hoping that that would get out of there and I would be fine. But it just didn’t work out that way.”

DeGrom spent his first nine big league seasons with the Mets, but was limited by injuries to 156 1/3 innings over 26 starts during his last two years in New York.

He had a career-low 1.08 ERA over 92 innings in 2021 before missing the final three months of the season with right forearm tightness and a sprained elbow.

The four-time All-Star didn’t make his first big league start last year until Aug. 2 after being shut down late in spring training because of a stress reaction in his right scapula.

His latest injury almost surely will trigger Texas’ conditional option on deGrom’s contract for 2028.

The option takes effect if deGrom has Tommy John surgery on his right elbow from 2023-26 or has any right elbow or shoulder injury that causes him to be on the IL for any period of 130 consecutive days during any season or 186 days in a row during any service period.

The conditional option would be for $20 million, $30 million or $37 million, depending on deGrom’s performance during the contract and health following the 2027 season.

“I feel bad for Jake. If I know Jake, he’ll have the surgery and come back and finish his career strong,” second-year Mets manager Buck Showalter said. “I know how much it means to him. He enjoys pitching. It’s certainly sad news for all of us.”